Preferential Procurement Regulations: Impact on Health Sector Suppliers in 2026

By João L. Carapinha

May 8, 2026

Preferential Procurement Regulations

South Africa’s Preferential Procurement Regulations, embedded in the Draft General Public Procurement Regulations, 2026, introduce mandatory set-asides, pre-qualification tests and subcontracting thresholds that directly affect suppliers of active pharmaceutical ingredients, diagnostics and hospital equipment. These rules, drawn from sections 17–23 of the Public Procurement Act, 2024 and regulations 55–70, replace discretionary preferences with clear ownership and spend requirements across contract values.

Lower-Value Tender Set-Asides

Regulation 56 confines set-asides to contracts or unbundled lots up to R20 million when at least three qualifying suppliers exist. Procuring entities must ring-fence minimum budget shares for 100 % black-owned, black-women-owned, youth-owned, disability-owned and cooperative suppliers listed in Annexure 2. A malaria rapid-test tender valued at R18 million, for instance, could be reserved solely for 100 % black-women-owned small firms meeting geographic criteria. Non-compliant bids are disqualified immediately. Where no qualifying offers appear, institutions must cancel and re-advertise or file a regulation 55 report.

Mid-Value Contract Pre-Qualification

For tenders between R20 million and R100 million, regulation 59 applies pre-qualification under section 18. Bidders must show either 40 % of prior spend with 51 % black-owned entities or commit to subcontracting 30 % of contract value to 100 % citizen-owned enterprises. A R65 million infusion-pump tender would therefore require foreign suppliers to prove historical compliance or secure eligible local partners before technical scoring begins. Institutions must confirm at least three viable subcontractors exist; failure triggers disqualification.

Large-Contract Subcontracting Mandates

Above R100 million, regulation 62 imposes compulsory subcontracting of at least 25 % of contract value to 100 % citizen-owned entities in designated categories. Direct-payment and expedited-arbitration clauses protect subcontractors. A R250 million laboratory-consumables contract would oblige the prime contractor to allocate 25 % of revenue to compliant small enterprises, with the procuring institution authorised to pay them directly. Substitutions are allowed only when replacements meet identical standards.

Regulations 67–70 allow institutions to add sustainability, local-content and job-creation conditions. Breaches attract penalties, payment retentions or debarment. When preference measures cannot be applied, a regulation 55 report to the Public Procurement Office is required. The 70 % minimum threshold on each criterion prevents superficial compliance.

Supplier Structuring Strategies

Health-sector companies can meet the Preferential Procurement Regulations through joint ventures, strategic subcontracting partnerships and localisation of formulation or assembly activities. Early supplier-database registration and auditable ownership records remain essential for sustained eligibility.

Reference url

Recent Posts

biologic dispensing implementation gaps
Biologic Dispensing Implementation Gaps Challenge Patient Access to Care

By João L. Carapinha

July 7, 2026

Biologic dispensing implementation gaps are undermining equitable access to advanced therapies for inflammatory bowel disease across Portugal’s public hospitals. Despite clear legislative changes, institutions continue to reject prescriptions for biologics written by private specialists, forcing ...
curative therapy commercialization gap
Curative Therapy Commercialization Gap and Global Access Challenges

By João L. Carapinha

July 7, 2026

The curative therapy commercialization gap remains one of healthcare’s most stubborn contradictions: cell and gene therapies can deliver complete disease resolution, yet structural, financial, and infrastructural barriers keep them from reaching most patients who need them. This disconnect is esp...
transatlantic reference pricing innovation
Transatlantic Reference Pricing Innovation and Its Impact on Global Pharmaceutical Dynamics

By João L. Carapinha

July 7, 2026

The transatlantic reference pricing innovation is fundamentally altering pharmaceutical revenue expectations and patient access on both sides of the Atlantic. By anchoring U.S. reimbursement to the second-lowest net price among a basket of wealthy nations, the Most Favored Nation (MFN) policy cre...